PROFILE OF PROSTATE CANCER PATIENTS AT DR. MOEWARDI HOSPITAL PERIOD JANUARY 2017 – JANUARY 2022: RETROSPECTIVE STUDY
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: This study aims to know the profile of prostate cancer patients treated at Moewardi General Hospital from January 2017 to January 2022. Material & Methods: A retrospective study was conducted in prostate cancer patients who have or are undergoing therapy at Moewardi General Hospital from January 2017 to January 2022 using purposive sampling techniques. Results: From January 2017 to January 2022, 441 male patients were diagnosed with prostate cancer which is dominated able to go home alive, around 92.97%. The age of study subjects was overlooked of 70-80 years with a total of 182 people, dominated by self-employed as many as 420 people. The breakdown of PSA scores of 1-20 in as many as 247 people, Adeno Ca Prostate as many as 374 people with the majority of prostate Ca cases in subjects in non-metastatic status (359 people). The results of variable Rectal Toucher examination described results dominated by palpable prostate and hard as many as 437 people. Conclusion: The most important prognostic indicators in prostate cancer are the patient's age and general health at the time of diagnosis, the cancer stage, the level of pre-therapeutic PSA, and the Gleason score. A worse prognosis is associated with high levels of the disease, more advanced stages, younger age, and elevated levels of PSA. Keywords: Prostate cancer, patient’s age, PSA, male.
##plugins.themes.bootstrap3.article.details##
prostate cancer, patient profile, PSA, male
Chen FZ, Zhao XK. Prostate cancer: Current treatment and prevention strategies. Iran Red Crescent Med J. 2013; 15(4): 279–84.
W. Leslie MKDS. Prostate specific antigen. StatPearls. 2022; 40(10): 755.
Benafif S, Kote-Jarai Z, Eeles RA. A review of prostate cancer Genome-Wide Association Studies (GWAS). Cancer Epidemiol Biomarkers Prev. 2018; 27(8): 845–57.
Nieder C, Haukland E, Pawinski A, Dalhaug A. Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases. BMC Urol. 2010; 10(December).
Bleyer A, Spreafico F, Barr R. Causation of increased prostate cancer in young men. Oncoscience. 2021; 8: 37–9.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
Chen N, Zhou Q. The evolving gleason grading system. Chinese J Cancer Res. 2016; 28(1): 58–64.
Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J. 2018; 285(16): 2944–71.
Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018; 50(7): 928–36.
Liao Q, Long C, Deng Z, Bi X, Hu J. The role of circulating adiponectin in prostate cancer: A meta-analysis. Int J Biol Markers. 2015; 30(1): e22–31.
Ko YH. Functional recovery after radical prostatectomy for prostate cancer. Yeungnam Univ J Med. 2018; 35(2): 141–9.
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021; 149(4): 778–89.
Perdana NR, Mochtar CA, Umbas R HA. The Risk Factors of Prostate Cancer and Its Prevention: A Literature Review. Acta Med Indones. 2018; 48(3): 228–38.
American Cancer Society. 2022-cancer-facts-and-figures (n.d). 2022.
Filella X, Fernández-Galan E, Bonifacio RF, Foj L. Emerging biomarkers in the diagnosis of prostate cancer. Pharmgenomics Pers Med. 2018; 11: 83–94.
Bleyer A, Spreafico F, Barr R. Prostate cancer in young men: An emerging young adult and older adolescent challenge. Cancer. 2020; 126(1): 46–57. A
Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019; 10(2): 63–89.
Suzman DL, Boikos SA, Carducci MA. Bone-targeting agents in prostate cancer. Cancer Metastasis Rev. 2014; 33(2–3): 619–28.
Wang G, Zhao D, Spring DJ, Depinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018; 32(17–18): 1105–40.
Buhmeida A, Pyrhönen S, Laato M, Collan Y. Prognostic factors in prostate cancer. Diagn Pathol. 2006; 1(1): 1–15.
Bethesda (MD). PDQ Adult Treatment Editorial Board. Natl Cancer Inst. 2022; 38(5): 225–58.
Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front Public Heal. 2022; 10(February).
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–49.
Siegel, D. A., Mary, O’neil, E., Richards, T. B., Dowling, N. F., & Weir HK. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017. 2020.
Strassberg DS, Zavodni SM, Gardner P, Dechet C, Stephenson RA, Sewell KK. Quality of Life Following Prostatectomy as a Function of Surgery Type and Degree of Nerve Sparing. Curr Urol. 2017; 11(1): 16–20.